HBMN:SWX
HBM Healthcare Investments AG
223,00 CHF
arrow_upward
+0,22%(+0,50) 1G
18 nov, 13:16:42 GMT+1 · CHF
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per HBMN in corso…
Apertura
222,50 CHF
Massimo
223,00 CHF
Minimo
219,50 CHF
Cap. mercato
1,48 Mld
Vol. medio
5,81K
Volume
6,83K
Dividendo
4,04%
Dividendo trimestrale
2,25 CHF
Data di stacco dividendo
17 giu 2026
Rapporto P/E
4,19
Max 52 sett.
258,00 CHF
Min 52 sett.
198,60 CHF
Utili per azione
53,19 CHF
Azioni in circolazione
6,62 Mln
Apertura
222,50 CHF
Massimo
223,00 CHF
Minimo
219,50 CHF
Cap. mercato
1,48 Mld
Vol. medio
5,81K
Volume
6,83K
Dividendo
4,04%
Dividendo trimestrale
2,25 CHF
Data di stacco dividendo
17 giu 2026
Rapporto P/E
4,19
Max 52 sett.
258,00 CHF
Min 52 sett.
198,60 CHF
Utili per azione
53,19 CHF
Azioni in circolazione
6,62 Mln
Articoli giornalistici
Da fonti web e partner giornalistici
Milano Finanza
·
4 ore fa
VON TB SH DOW JONES 51500 B 51500 181226
Teleborsa
·
5 ore fa
Analisi Tecnica: indice Nasdaq Composite del 17/11/2026
Teleborsa
·
5 ore fa
Analisi Tecnica: indice S&P 500 del 17/11/2026
FOREX.com
·
43 minuti fa
S&P 500 Quietly Shrugs Off the Bitcoin and Silver Selloff
Profilo
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Informazioni su HBM Healthcare Investments AG
CEO-
Dipendenti-
Data di fondazione12 lug 2001
SedeZugo, Zugo, Svizzera
SettoreFinancials
Settore-
Sito webhbmhealthcare.com